Drug Search Results
Using advanced filters...
Advanced Search [+]

Bamosiran

Alternative Names: bamosiran, syl-040012, syl040012, syl 040012
Clinical Status: Inactive
Latest Update: 2024-05-05
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADRB2 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Ocular,Topical,Ophthalmic

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sylentis
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Glaucoma, Open-Angle|Hypertension|Glaucoma

Phase 1: Hypertension|Glaucoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CUNFI-0511-0814

P1

Completed

Glaucoma|Hypertension

2010-06-01

2019-03-19

Treatments

SYLTAG

P2

Completed

Glaucoma

2015-08-05

2025-07-02

Treatments

SYLTAG

P2

Completed

Hypertension|Glaucoma, Open-Angle

2015-08-01

2020-11-05

SYL040012_III

P2

Completed

Hypertension|Glaucoma, Open-Angle

2013-05-01

2019-03-19

Treatments

2011-001849-33

P2

Completed

Glaucoma, Open-Angle|Hypertension

2013-04-30

2022-03-13

Treatments

SYL040012_II

P2

Completed

Glaucoma|Hypertension

2012-03-01

2019-03-19

Treatments